

Brilliant Violet 785™ anti-human CD3 Antibody

Catalog# / Size	317329 / 25 tests 317330 / 100 tests
Clone	OKT3
Regulatory Status	RUO
Workshop	HCDM listed
Other Names	T3, CD3ε
Isotype	Mouse IgG2a, κ
Description	CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details

Verified Reactivity	Human
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.</p> <p>Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	<p>The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.</p> <p>Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include:</p>

immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/μg).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, *et al.* 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, *et al.* 2005. *Immunology* 116:487.
5. Jeong HY, *et al.* 2008. *J. Leukocyte Biol.* 83:755. [PubMed](#)
6. Alter G, *et al.* 2008. *J. Virol.* 82:9668. [PubMed](#)
7. Manevich-Mendelson E, *et al.* 2009. *Blood* 114:2344. [PubMed](#)
8. Pinto JP, *et al.* 2010. *Immunology.* 130:217. [PubMed](#)
9. Biggs MJ, *et al.* 2011. *J. R. Soc. Interface.* 8:1462. [PubMed](#)

Product Citations

1. Ivarsson M, *et al.* 2016. *Mucosal Immunol.* 10.1038/mi.2016.50. [PubMed](#)
2. Robinson GA, *et al.* 2021. *EBioMedicine.* 103243. [PubMed](#)
3. Tatari N, *et al.* 2022. *Front Immunol.* 13:905768. [PubMed](#)
4. Arce Vargas F *et al.* 2018. *Cancer cell.* 33(4):649-663. [PubMed](#)
5. Leeansyah E, *et al.* 2015. *PLoS Pathog.* 11: 1005072. [PubMed](#)
6. Novakova L *et al.* 2018. *Journal of neurochemistry.* 146(3):322-332. [PubMed](#)
7. Zhou R, *et al.* 2020. *Immunity.* S1074-7613(20)30333-2. [PubMed](#)
8. Karim F, *et al.* 2021. *Elife.* 10. [PubMed](#)
9. Myers JA, *et al.* 2022. *JCI Insight.* [PubMed](#)
10. Hinterbrandner M, *et al.* 2021. *JCI Insight.* 6:e151797. [PubMed](#)
11. Asowata OE, *et al.* 2021. *JCI Insight.* 6. [PubMed](#)
12. Björklund &, *et al.* 2016. *Nat Immunol.* 17:451-460. [PubMed](#)
13. Ollé Hurtado M, *et al.* 2019. *PLoS One.* 14:e0216373. [PubMed](#)
14. Wang N, *et al.* 2021. *iScience.* 24:103205. [PubMed](#)
15. Lisovsky I, *et al.* 2015. *J Virol.* 89: 9909 - 9919. [PubMed](#)
16. Fisher J, *et al.* 2017. *Mol Ther.* 10.1016/j.ymthe.2017.03.002. [PubMed](#)
17. Jackson E, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0185160. [PubMed](#)
18. Caduff N, *et al.* 2021. *Cell Reports.* 35(5):109056. [PubMed](#)
19. Jin Y *et al.* 2019. *Nature communications.* 10(1):391. [PubMed](#)
20. Neff CP *et al.* 2018. *EBioMedicine.* 30:192-202. [PubMed](#)
21. Davis JE, *et al.* 2021. *J Transl Med.* 19:473. [PubMed](#)
22. Nel I, *et al.* 2021. *Diabetologia.* 64(10):2306-2321. [PubMed](#)
23. Wu X, *et al.* 2018. *J Immunol Methods.* 455:71. [PubMed](#)
24. Moore T, *et al.* 2017. *Cancer Immunol Immunother.* 10.1007/s00262-017-2073-0. [PubMed](#)
25. Huber JE, *et al.* 2020. *J Immunol.* 204:1101. [PubMed](#)
26. Li N, *et al.* 2021. *Cell Rep Med.* 2:100297. [PubMed](#)
27. Waddington KE, *et al.* 2020. *Front Immunol.* 1.51875. [PubMed](#)
28. Isitman G, *et al.* 2016. *PLoS One.* 11:e0164517. [PubMed](#)
29. Thieme CJ, *et al.* 2020. *Cell Rep Med.* 1:100092. [PubMed](#)
30. Tuong ZK, *et al.* 2021. *Cell Rep.* 37:110132. [PubMed](#)
31. Singh A, *et al.* 2020. *Cell Rep.* 32:108153. [PubMed](#)
32. Bradley D, *et al.* 2022. *Nat Commun.* 13:5606. [PubMed](#)
33. Menges D, *et al.* 2022. *Nat Commun.* 13:4855. [PubMed](#)
34. Kim MY, *et al.* 2022. *Nat Commun.* 13:3296. [PubMed](#)
35. FitzPatrick MEB, *et al.* 2021. *Cell Rep.* 34:108661. [PubMed](#)
36. Wu X, *et al.* 2020. *Front Immunol.* 1.922222222. [PubMed](#)
37. Martinez EM, *et al.* 2018. *SLAS Discov.* 1.377083333. [PubMed](#)
38. Abd Hamid M *et al.* 2019. *Cancer Immunol Res.* 7(8):1293-1306. [PubMed](#)
39. Bruno L, *et al.* 2016. *Immunol Cell Biol.* 10.1038/icb.2016.49. [PubMed](#)
40. Ferreira-Gomes M, *et al.* 2021. *Nat Commun.* 12:1961. [PubMed](#)
41. Dersh D, *et al.* 2020. *Immunity.* 54(1):116-131.e10. [PubMed](#)
42. Ogongo P, *et al.* 2020. *J Clin Invest.* 130:214. [PubMed](#)

RRID

AB_11219196 (BioLegend Cat. No. 317329)
AB_2563507 (BioLegend Cat. No. 317330)

Antigen Details

Structure	Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution	Mature T and NK T cells, thymocyte differentiation
Function	Antigen recognition, signal transduction, T cell activation
Ligand/Receptor	Peptide antigen bound to MHC
Cell Type	NKT cells, T cells, Thymocytes, Tregs

Biology Area Immunology
Molecular Family CD Molecules

Antigen References

1. Barclay N, *et al.* 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, *et al.* 1981. *Eur. J. Immunol.* 11:329.
3. Lanier L, *et al.* 1986. *J. Immunol.* 137:2501.

Gene ID [916](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Purified anti-human CD3, FITC anti-human CD3, PE anti-human CD3, Alexa Fluor® 488 anti-human CD3, Alexa Fluor® 647 anti-human CD3, Pacific Blue™ anti-human CD3, APC anti-human CD3, Biotin anti-human CD3, Brilliant Violet 605™ anti-human CD3, Brilliant Violet 650™ anti-human CD3, Ultra-LEAF™ Purified anti-human CD3, Brilliant Violet 711™ anti-human CD3, Brilliant Violet 785™ anti-human CD3, Brilliant Violet 510™ anti-human CD3, PE/Cyanine7 anti-human CD3, PerCP/Cyanine5.5 anti-human CD3, PerCP anti-human CD3, Alexa Fluor® 700 anti-human CD3, APC/Cyanine7 anti-human CD3, Brilliant Violet 421™ anti-human CD3, PE/Dazzle™ 594 anti-human CD3, APC/Fire™ 750 anti-human CD3, GMP Ultra-LEAF™ Purified anti-human CD3 SF, PE/Cyanine5 anti-human CD3 Antibody

Product Data



Human peripheral lymphocytes were stained with CD3 (clone OKT3) Brilliant Violet 785™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587